Moderna reported Q1 2026 revenue of $389 million, surpassing estimates of $251.8 million, driven by strong COVID-19 vaccine sales internationally. However, the company posted a GAAP net loss of $1.3 billion, wider than expected, mainly due to a one-time $0.9 billion litigation settlement charge. Excluding this charge, costs declined year-over-year. Moderna expects up to 10% revenue growth in 2026 and is advancing new product approvals and clinical trials, including cancer therapy studies. The company’s cash reserves fell slightly to $7.5 billion due to operating losses and investments.
The ROBO Global Healthcare Technology and Innovation ETF (HTEC) has outperformed in 2026 by focusing on specialized healthcare technology sectors like genomics, diagnostics, and medical instruments. Key contributors include Twist Bioscience, Moderna,...
Wall Street ended the holiday-shortened week higher, driven by optimism over a potential Federal Reserve interest rate cut by year-end despite weaker-than-expected June jobs data. Technology stocks rebounded early in the week amid easing U.S.-Iran te...
